Rhino-Conjunctivitis Industry Professional Survey About Therapeutics And Pipeline Review H2 2017

Overview

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740084-rhino-conjunctivitis-pipeline-review-h2-2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 9, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

 Major Scope of the report:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology). 
- The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects. 

- The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. 

Table of Contents 

List of Tables 
List of Figures 
Introduction 
Global Markets Direct Report Coverage 
Rhino-Conjunctivitis - Overview 
Rhino-Conjunctivitis - Therapeutics Development 
Pipeline Overview 
Pipeline by Companies 
Pipeline by Universities/Institutes 
Products under Development by Companies 
Products under Development by Universities/Institutes 
Rhino-Conjunctivitis - Therapeutics Assessment 
Assessment by Target 
Assessment by Mechanism of Action 
Assessment by Route of Administration 
Assessment by Molecule Type 
Rhino-Conjunctivitis - Companies Involved in Therapeutics Development 
ALK-Abello AS 
Allergopharma GmbH & Co KG 
Allergy Therapeutics Plc 

 .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2740084-rhino-conjunctivitis-pipeline-review-h2-2017

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.